J&J raises talc settlement to $8.9 billion, unit files for a second bankruptcy
HQ Team April 5, 2023: Johnson and Johnson, a US multinational making pharmaceuticals and medical devices, has offered to pay $8.9 billion to.
Drugs
Medical
Pharma
BioNTech, Duality Biologics sign $1.5 billion pact for cancer drugs
HQ Team April 3, 2023: BioNTech SE and Duality Biologics (Suzhou) have signed a $1.5 billion deal to develop and commercialise two cancer.
Drugs
Medical
Pharma
Yemen, Lebanon allege India’s Celon Labs’ drug ‘substandard’
The WHO has issued a medical product alert on a contaminated cancer and autoimmune disease treatment drug made by Hyderabad, India-based Celon Laboratories,.
Drugs
Medical
Pharma
BioNTech in one million euro push for research on drugs
BioNTech, a Germany-based biotechnology company, is expected to spend between 2.4 million euros and 2.6 million euros on research this year compared with.
Drugs
Medical
Pharma
Glenmark gets FDA nod for trials in US on tumour, cancer patients
Glenmark Specialty SA, a subsidiary of India’s Glenmark Pharmaceuticals, has got investigational new drug clearance from the FDA to conduct clinical trials in.
Drugs
Health
Medical
Leukaemia drug effective in treating breast cancer metastatic relapse
A mice study showed promising results in treating secondary recurrence of breast cancer in lungs
Drugs
Medical
Pharma
Pfizer to buy Seagen for $43 billion to fortify cancer portfolio
Pfizer will acquire Seagen for $43 billion to beef up its cancer portfolio, with COVID-19 vaccine sales forecast to plummet.
Drugs
Pharma
Redx, Jounce to merge in a $425 million all-share deal
Redx Pharma, based in the UK and Jounce Therapeutics, US, will merge in an all-share transaction worth $425 million to establish a new.
Drugs
Health
Pharma
Embedded LEDs may aid future cancer immunotherapies
Activation of bio-therapeutic drugs by switching on LEDs embedded close to a tumour may be cancer immunotherapy's future, researchers found.
Drugs
Medical
Pharma
GE Healthcare recalls 688 medical systems, FDA says ‘most serious’
GE Healthcare has pulled out 688 medical systems that evaluate diseases, trauma, abnormalities and disorders, a move which USFDA termed a most severe.